The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,048.00
Ask: 12,050.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,098.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Ashtead Rises On Strong Earnings And Buyback Plans

Tue, 18th Jun 2019 08:49

(Alliance News) - Stock prices in London opened flat on Tuesday, with Ashtead rising after strong annual results, helping the FTSE 100 to outperform other European indices.The UK blue-chip index was up just 3.58 points at 7,360.68. The mid-cap FTSE 250 was down 51.10 points, or 0.3%, at 19,106.51. The AIM All-Share was up 0.17 point at 937.63.The Cboe UK 100 index was up 0.1% at 12,496.39. The Cboe UK 250 was down 0.1% at 17,165.89, and the Cboe UK Small Companies was flat at 11,647.12.In European equities, the CAC 40 stock index in Paris was down 0.1% and the DAX 30 in Frankfurt was down 0.6%.In the FTSE 100, Ashtead Group was up 0.7%, after the equipment rentals firm reporting a strong set of annual results for financial 2019, while also announcing plans for a GBP500 million share buyback.For the financial year ended April 30, revenue rose 19% to GBP4.49 billion from GBP3.71 billion the year before, and pretax profit rose 20% to GBP1.06 billion from GBP862.1 million. The company said it continued to enjoy strong end-markets in North America and was executing well on its strategy of organic growth supported by targeted bolt-on acquisitions.Ashtead proposed a final dividend of 33.5 pence, bringing a total payout 40.0 pence, up 21% from 33.0p in financial 2018.Interactive Investor's Richard Hunter said: "It is the company's very reliance on the US which tends to spook investors, however. Given Ashtead's previous mauling during the financial crisis following a sharp downturn in the construction space, it seems that investors may have been once bitten and twice shy. "Net debt remains high at around GBP4 billion which, whilst currently containable given the group's cash generation, would prove to be an immediate noose in the event of a downturn in the US, which on a wider basis is the current topic of debate given some mixed economic numbers of late. In addition, such an acquisitive nature always carries execution risk, while from an investment perspective the dividend yield of around 2% still seems uninviting."AstraZeneca was up 0.5% after the Anglo-Swedish drugmaker and Merck & Co said the European Commission has approved Lynparza as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.At the other end of the large cap index, Evraz was the worst performer, down 2.2% after Citigroup downgraded the Russian steelmaker to Sell from Neutral. InterContinental Hotels Group was down 1.9% after Barclays cut the hotel operator to Underweight from Equal Weight. In the FTSE 250, Telecom Plus was the best performer, up 2.5%. The multi utility services provider said it delivered annual results for financial 2019 in line with expectations. For the year ended March 31, revenue rose 1.5% to GBP804.4 million from GBP792.9 million the year before, and pretax profit increased 4.9% to GBP43.0 million from GBP41.0 million. Adjusted pretax profit increased by 3.7% to GBP56.3 million from GBP54.3 million in 2018. The company said that in the absence of "unforeseen circumstances" it expect adjusted pretax profit for financial 2020 to be between GBP60 million and GBP65 million. The US Federal Reserve's policy-setting Federal Open Market Committee, which is scheduled to meet later on Tuesday and Wednesday, is widely expected to hold interest rates unchanged this month, although it is very likely to signal a rate cut sometime in the near term. The policy announcement is due at 1900 BST on Wednesday."Tomorrow's FOMC hangs over the markets, and today ought to be quiet, but there's an air of nervousness around," noted Societe Generale's Kit Juckes. The Japanese Nikkei 225 index closed down 0.7%. In China, the Shanghai Composite closed up 0.1%, while the Hang Seng index in Hong Kong is up 1.2%.The pound was quoted at USD1.2538 Tuesday, lower than USD1.2559 at the London equities close Monday.The battle for the Conservative party crown in the UK is revving up with a fresh round of voting in the leadership stakes as Boris Johnson is due to break cover and take part in television debates.Tory MPs will vote in the second bout of the contest to select the UK's next prime minister on Tuesday ahead of a live TV debate that will feature the front-runner and former foreign secretary, Johnson.Candidates need to gain at least 33 votes from MPs to remain in the race to reach the final run-off, which will see some 160,000 Tory members select the next prime minister.If all candidates pass the 33-vote threshold, the one with the lowest total will be eliminated and by the end of the week, four of the six current riders will be forced out, leaving the final two to go head-to-head for votes from the Tory grassroots.The economic events calendar on Tuesday has eurozone inflation readings at 1000 BST and US housing starts at 1330 BST. In addition, European Central Bank President Mario Draghi and Bank of England Governor Mark Carney will speak on the second day of the ECB's annual three-day forum in Sintra, Portugal at 0900 BST and 1500 BST, respectively.

More News
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.